论文部分内容阅读
全球大约有2 300万人患有心力衰竭,对β-肾上腺素受体的反应性降低是心力衰竭的特征并由此导致心脏功能异常。通过转基因的办法抑制β-肾上腺素能受体激酶1(βARK1)进而改善衰竭心脏的收缩功能和对β-肾上腺素能神经兴奋的反应性,使得βARK1的抑制成为重要的治疗心力衰竭的手段。本文就βARK1研究的最新进展作一综述。
About 23 million people worldwide suffer from heart failure, and a decreased response to β-adrenergic receptors is a hallmark of heart failure and thus leads to cardiac dysfunction. Inhibition of β-adrenergic receptor kinase 1 (βARK1) by transgenesis further improves the contractile function of the failing heart and the responsiveness to β-adrenergic nerve excitability, making inhibition of βARK1 an important means of treating heart failure. This article reviews the latest progress of βARK1 research.